廖伟科，博士，教授，青年博士生导师、硕士研究生导师。国家自然科学基金通讯评审专家，全国新增博士学位授权点评议专家。主持国家自然科学基金青年基金、国自然地区基金及省部级项目共计6项。研究成果发表在Chem. Eng. J. (IF = 13.3),Mol. Biomed. (IF = 10.7),Eur. J. Med. Chem.,等药学权威期刊上。获授权发明专利7项，贵州省医学科技奖二等奖一项，贵州省药学科技奖三等奖一项。
联系方式：641212891@qq.com
【学习及工作经历】
2016.08-至今 k1十年体育品牌
2015.07-2016.07 福建省微生物研究所
2010.09-2015.07 沈阳药科大学 药物化学 博士学位
2006.09-2010.07 沈阳药科大学 药物制剂 学士学位
【研究领域】
主要围绕肿瘤等复杂性疾病的重大临床需求，开展合理的药物设计，为克服临床上应用激酶抑制剂后所产生的获得性耐药提供候选分子。此外，针对现有上市的抗肿瘤药物所存在的不足进行有针对性的改进，为实现肿瘤病人的精准治疗提供一定的物质基础。
【代表性成果】
1.科研项目：
(1)国家自然科学基金,靶向正构或变构位点的选择性PI3Kα抑制剂的设计、合成及抗肿瘤活性评价，在研,主持；
(2)国家自然科学基金,基于吡啶/嘧啶母核的c-Met抑制剂的设计、合成及抗肿瘤活性评价，已结题,主持；
(3)贵州省科技支撑计划,MET-TKI在非小细胞肺癌获得性耐药上的机制探索及药物研究，在研，项目实施人;
(4)贵州省科技计划项目，基于“共价修饰策略”的选择性PI3Kα抑制剂的设计合成及抗肿瘤活性研究，在研，主持;
(5)贵州省科技支撑计划,黔科合支撑2019[2761]号,利格列汀衍生物LGT-6成药性研究,已结题，主持；
2.近五年代表性论文：
(1) Yongrui Hai#, Ruizhuo Lina#,Weike Liao#, Renming Fan#, Junyan Zhuang, Bingjie Zhang, Junke Song*, Gaofei Wei*. Modulation of Pyrimidine Metabolism via DHODH Inhibition Promotes NK Cell Infiltration for Enhanced Melanoma Immunotherapy.Molecular Biomedicine,2025, 6:87. (IF = 10.7).
(2) Zhongyuan Wang1, Xinfu Liu1, Youli Hou, Dongdong Cao, Shiyu Hu, Lihong He, Yiwei Zhang, Dongsheng Zhao, Rui Chen, Wenzhang Chen, Aihong Li***, Weiwei Ouyang**,Weike Liao*. Identification of 2,4-disubstitued pyridine derivatives as potent FMS-like tyrosine receptor kinase 3 (FLT3) inhibitors.BioorganicChemistry,2025, 167: 109229.(IF =4.7).
(3)Shengfei Wu1,Pengjuan Zhao1, Youli Hou1,Lihong He1,Zhongyuan Wang, Dan Yang,Lijie Sima,Aihong Li,Xing Cui,Dongsheng Zhao, Bilan Luo,Jianta Wang, Lan Liu***,Weike Liao**,Yu Zhang*.Design, synthesis, and biological evaluation of pyridine-based derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia.European Journal of Medicinal Chemistry, 2025, 289: 117492. (IF = 6.0).
(4)Beijing Chen1, Zhongyuan Wang1, Qi Chen1, Ying Zhang1, Yu Zhang, Aihong Li, Shengfei Wu, Weiwei Ouyang, Lijie Sima, Xiaoxu Li, Dongsheng Zhao, Bilan Luo, Jianta Wang, Lei Tang*, Xiaoming Su*,Weike Liao*.Discovery of pyridine-based derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia.European Journal of Medicinal Chemistry, 2025, 283:117173. (IF = 6.0).
(5)Junyan Zhuang#,Renming Fan#,Weike Liao#,Ruizhuo Lin, Aohua Deng,Ting Zhao,Yongrui Hai,Heran Li,Lei Tang*,Gaofei Wei*.Organelle Synergy Unleashed: Modulating MitochondrialEndoplasmic Reticulum Contacts with a Self-Assembled Prodrug Amplifies Ferroptosis for Innovative Cancer Therapy.Chemical Engineering Journal, 2024, 495: 153364. (IF = 13.3).
(6).Tingting Wu1, HuCheng1, Lijie Sima1, ZhongyuanWang, Weiwei Ouyang, Jianta Wang, Yunlei Hou,Dongsheng Zhao*,Weike Liao*,Chujiao Hu*.Identification of novel PD-1/PD-L1 small moleculeinhibitors:virtual screening, synthesis and in vitro characterization.Journal of Enzyme Inhibition and Medicinal Chemistry, 2024, 39(1): 2353711.(IF = 5.6).
(7)Rui Chen; Zhongyuan Wang; Lijie Sima; Hu Cheng; Bilan Luo; Jianta Wang; Bing Guo; ShunyiMao; Zhixu Zhou; Jingang Peng; Lei Tang; Xinfu Liu*;Weike Liao*; Design, synthesis and evaluationof 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3Kα inhibitors,Journal of EnzymeInhibition and Medicinal Chemistry, 2023, 38(1): 2155638.(IF = 5.6).
(8)Weike Liao1, Yu Zhang1, Zhixu Zhou, Xing Cui, Jianta Wang, Zhongyuan Wang∗,
Lei Tang*.Synthesis, structural analysis, vibrational properties, and chiralseparation of Xanthine-Quinazoline diastereomers,Journal of Molecular Structure,2022,1253:132311. (IF = 4.0).
(9)Weike Liao; Zhongyuan Wang; Yufei Han; Yinliang Qi; Jiaan Liu; Juan Xie; Ye Tian; Qiancheng Lei; Rui Chen; Ming Sun; Lei Tang; Guowei Gong; Yanfang Zhao; Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3Kα inhibitors with potent antitumor activity,European Journal of Medicinal Chemistry, 2020, 197: 112309.(IF =6.7).
